MOLECULAR PARTNERS AG
Business
Molecular Partners AG is a clinical-stage biotechnology company that designs and develops DARPin (Designed Ankyrin Repeat Protein) therapeutics to address medical challenges not readily met by other modalities. It develops DARPin-based product candidates including multi-specific immune cell engagers, tumor‑localized CD40 activators, radio‑DARPin radiotherapies and Switch‑DARPin conditional activators. Key business areas include its oncology pipeline (notably MP0533 and MP0317), the Radio‑DARPin Therapy (RDT) platform, the Switch‑DARPin platform and strategic collaborations with industry partners. The company advances programs through global clinical trials, academic and industry collaborations and third‑party manufacturing and distribution channels.
Summary from filing dated 2025-03-06
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-61.65M |
| Total assets | $102.11M |
| Total liabilities | $21.77M |
| Stockholders' equity | — |
| Operating cash flow | — |